FIELD: medicine, pharmaceutics.
SUBSTANCE: group of invention refers to medicine, namely to oncology, and can be used in treating cancer in a patient. The method involves administering at least one encapsulated chemotherapeutic agent, and at least one amphiphilic block copolymer in this patient. What is also presented is a composition, a kit for treating cancer in the patient and using the amphiphilic block copolymer.
EFFECT: group of inventions provides potentiating the encapsulated chemotherapeutic agent by stimulating the active chemotherapeutic agent release from liposomes by the use of the amphiphilic block copolymer, which is poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer, in the composition.
10 cl, 11 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING BIOLOGICAL AGENT | 1996 |
|
RU2166934C2 |
| LIPOSOMAL COMPOSITIONS APPLICABLE FOR DRUG DELIVERY | 2005 |
|
RU2574926C2 |
| HYPER-STABILIZED LIPOSOMES INCREASING DIRECTED TARGETING OF MITOTIC CELLS | 2018 |
|
RU2765736C2 |
| STABLE ANTI-TUMOR MEDICINE, METHOD FOR ITS PREPARATION AND APPLICATION | 2017 |
|
RU2676279C1 |
| LIPOSOMAL ANTITUMOR COMPOSITIONS | 2017 |
|
RU2756837C2 |
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
| DOXORUBICIN AND ORGANOSILICON NANOPARTICLES-NIOSOMES- BASED PHARMACEUTICAL GEL FOR SKIN CANCER TREATING | 2014 |
|
RU2600164C2 |
| PHOSPHOLIPID COMPOSITION OF DOXORUBICIN FOR TREATING PATIENTS WITH BREAST CANCER | 2019 |
|
RU2714137C1 |
| LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
| STABLE EMULSION FOR PARENTERAL INTRODUCTION OF BADLY SOLUBLE IN WATER COMPOUNDS, WHICH HAVE ANTI-TUMOR ACTIVITY, AND METHOD OF ITS OBTAINING | 2007 |
|
RU2370261C2 |
